bluuebunny/crossref_metadata_2025_split huggingface dataset:
Validation of a tagalog version of the EORTC PATSAT-C33 and EORTC OUT-PATSAT7 patient satisfaction questionnaires for patients with cancer undergoing outpatient radiotherapy.
Authors: Castillo Michelle Regina , Canal Johanna Patricia , Jamora Kurl , Wong Harroun , Sumndad Al Muzani , Tan Anderson Kirk Nigel 
Published: August 2024

190 Background: The satisfaction of cancer patients with their care significantly impacts their quality of life. Beyond specific cancer treatments, the delivery of care plays a vital role. Evaluating patient satisfaction with care is increasingly important in oncology due to the prolonged and intensive nature of cancer management. Discussions often focus on medical aspects, neglecting administrative and psychosocial concerns. Patient-centered care involves assessing satisfaction, which reflects perceived quality. Patient satisfaction is now recognized as a key indicator of care quality. Methods: The EORTC developed tools like PATSAT-C33 and OUT-PATSAT7 to assess satisfaction with cancer care. These instruments, translated into Tagalog using a “forward-backward” translation procedure in accordance with the EORTC QOL Study Group guidelines, were validated among Filipino cancer patients undergoing radiotherapy. The tools encompass dimensions like doctors' skills, information exchange, nurses' responsiveness, and care organization. They showed reliability and validity comparable to the original versions. Results: Construct, criterion, and factorial validity were assessed, indicating the tools measure intended constructs effectively. The multi-item scales of EORTC PATSAT-C33 and EORTC OUT-PATSAT7 have good to excellent internal consistency. A value between 0.8 - 0.9 represents good reliability, whereas a Cronbach alpha of≥0.9 represents excellent reliability. Criterion validity was confirmed by comparing them with a validated Filipino satisfaction scale. Each dimension identified in the original study applies to Filipino cancer patients, suggesting the tools' applicability across populations. Conclusions: Despite some demographic biases in the study sample, the translations proved valid and reliable. These Tagalog versions are recommended for use with native Tagalog-speaking Filipino cancer patients. Further studies with larger sample sizes may enhance reliability. [Table: see text]
Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC).
Authors: Sitthideatphaiboon Piyada , Somlaw Nicha , Zungsontiporn Nicha , Ouwongprayoon Pongsakorn , Sukswai Narittee , Korphaisarn Krittiya , Poungvarin Naravat , Aporntewan Chatchawit , Hirankarn Nattiya , Vinayanuwattikun Chanida 
Published: August 2024

204 Background: Gut microbiota is considered a key player modulating the response to immune checkpoint inhibitors (ICI) in cancer. The effects of dietary pattern on this interaction is not well-studied. Methods: A prospective multicenter cohort of 95 patients with advanced non-small cell lung cancer (NSCLC) undergoing ICI therapy were enrolled. Stool shotgun metagenomic sequencing was performed. Three-day dietary patterns before ICI were assessed. Patients were categorized as hyperprogressive disease (HPD) if they exhibited a time to treatment failure of <2 months. All others were categorized as non-hyperprogressive disease (non-HPD). The correlation between dietary patterns, gut microbiome, and response to ICI therapy was analyzed. Results: In the multivariate analysis, high abundance of Firmicutes unclassified and the Ruminococcaceae family correlated with significantly diminished progression-free survival (PFS) with HR of 2.40 [ P=0.006] and 4.30 [ P=0.005], respectively. More specifically, within the subset of NSCLC patients treated solely with ICI therapy, high abundance of Intestinimonas and the Enterobacteriaceae family were associated with reduced PFS with HR of 2.61 [ P=0.02] and HR 3.34 [ P=0.005], respectively. In dietary pattern analysis, HPD group showed increased consumption of cholesterol, sodium, and fats beyond recommended levels compared to non-HPD group. This group also displayed a tendency towards higher food pattern scores characterized by significant intake of fat and dairy products. Conclusions: Our study revealed distinct association between the gut microbiome composition and treatment outcomes. Based on these findings, the overall composition of diet may play a pivotal role in ICI therapeutic outcomes. [Table: see text]
Hospitalization outcome of patients with lung cancer with COVID-19 infection: NIS 2020 analysis.
Authors: Suenghataiphorn Thanathip , Srikulmontri Thitiphan , Kulthamrongsri Narathorn , Tribuddharat Narisara , Naunsilp Piengpitch , Saowapa Sakditad , Xanthavanij Nutchapon 
Published: August 2024

212 Background: Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths globally. Recent data showed the detrimental effects of COVID-19 infection on other neoplasm conditions, causing increased mortality rates and complications. However, data on the precise effects of COVID-19 on hospitalized individuals with lung cancer are scarce. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to investigate the effects of COVID-19 infection on cases primarily admitted due to lung and bronchus cancer. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was inpatient mortality, with secondary outcomes including system-based complications. Statistical significance was established at a p-value of 0.05. Results: We identified 103,334 patients with a primary discharge diagnosis of lung and bronchus cancer. The mean age was 68.9 years; 50.5% were female. In the non-COVID group, Caucasians accounted for 75%, followed by Hispanics (12%). Of these, 0.36% (374/103,334) had a concurrent diagnosis of COVID-19 infection. In a survey multivariable logistic and linear regression model adjusting for patient and hospital factors, COVID-19 infection was associated with higher in-hospital mortality (aOR 5.39; 95% CI (3.01, 9.64), p < 0.001), higher mean length of stay (b 5.51; 95% CI (2.59, 8.43) p < 0.001), mean total hospital cost (b 10,683; 95% CI (784.32, 20,581.93) p = 0.034), shock (aOR 4.37; 95% CI (1.96, 9.91), p < 0.001), acute respiratory failure (aOR 2.23; 95% CI (1.30, 3.85), p = 0.004), mechanical ventilation usage (aOR 3.12; 95% CI (1.46, 6.66), p = 0.003) and acute kidney injury (aOR 2.71; 95% CI (1.54, 4.74), p < 0.001). We observed non-significant, but increased, risks of sepsis, SIRS, and coagulopathy in COVID-19-positive patients. Conclusions: In conclusion, our study underscores that COVID-19 infection is associated with higher in-hospital mortality and other major clinical outcomes in lung cancer, as well as increased economic burden and cost of stay. To definitively establish causal relationships between the observed factors and the reported clinical outcomes in this population, further longitudinal research is necessary.
Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.
Authors: Cheng Ying , Loong Herbert H. , Zhou Caicun , Nishino Kazumi , Lee Dae Ho , Lee Se-Hoon , Yang James Chih-Hsin , Liu Dan , Rajakumar Deborah , Han Hongmei , Puri Tarun , Lin Aimee Bence , Goto Koichi 
Published: August 2024

214 Background: In prior studies, the efficacy and safety of selpercatinib, a selective RET inhibitor, was consistent in RET+ NSCLC pts across geographies. As previously reported, LIBRETTO-431 met its primary endpoint of improved PFS by blinded independent central review (BICR) at the pre-planned interim analysis. Here we report the efficacy and safety from LIBRETTO-431 in pts from East Asia, a majority of the study population. Methods: LIBRETTO-431 (NCT04194944) is a randomized, open-label phase 3 trial comparing 1L selpercatinib vs control (platinum/pemetrexed +/- pembrolizumab). Geography (East Asia vs non-East Asia) was a stratification factor. BICR-assessed PFS, ORR and DOR were examined in pts from East Asia randomized with investigator’s intent to treat with pembrolizumab (ITT-pembro) if assigned to control. AE data were collected for all pts from East Asia who received at least one dose of selpercatinib or control (n=140). Results: Of 142 randomized pts from East Asia, 116 were included in the ITT-pembro population (selpercatinib: n=75, control: n=41). Baseline characteristics were well balanced, however the selpercatinib arm had slightly more pts from East Asia vs the control arm (58% vs 49%). In ITT-pembro pts from East Asia, with a median follow up of 19.4 mo and 21.2 mo in the selpercatinib and control arms respectively, the median PFS was not yet reached with selpercatinib (95% CI: 16.4-NE) vs 11.1 mo (95% CI: 7.0-16.8) with control. At 12 mo the PFS rate was 72.8% with selpercatinib vs. 41.7% with control. The ORR was 86.7% (95% CI: 76.8-93.4) with selpercatinib vs 61.0% (95% CI: 44.5-75.8) with control. Similar results were observed in pts from East Asia in the overall ITT population. The most common AEs reported in pts from East Asia on selpercatinib included elevated AST (73.6%), elevated ALT (70.3%), hypertension (60.4%), increased blood bilirubin (52.7%) and diarrhea (44.0%) while those reported with control included anemia (61.2%), elevated AST (49.0%), leukopenia (49.0%), neutropenia (44.9%) and elevated ALT (42.9%). A summary of safety data for selpercatinib vs control in pts from East Asia is presented in the table. Conclusions: LIBRETTO-431 is the first randomized study to report efficacy and safety of a RET inhibitor in pts from East Asia. Consistent with the results in the overall population, selpercatinib demonstrated superior PFS compared to chemotherapy + pembrolizumab in 1L pts from East Asia. These data support early comprehensive genomic testing and the use of selpercatinib as the preferred 1L regimen in RET+ NSCLC pts across geographies. Clinical trial information: NCT04194944 . [Table: see text]
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
Authors: Ma Vincent T. , Park Yeonhee , Patel Janmesh. D , Harris Madison S. , Mannino Matthew C. , Schehr Jennifer L. , Birbrair Alexander , Zhao Shuang , Lang Joshua Michael 
Published: August 2024

225 Background: ctDNA monitoring has shown promising results in predicting relapse in resected solid tumors. Its role in treatment response assessment and predicting survival outcomes in the unresectable or metastatic disease setting merits further investigation. In our study, we attempt to assess the role of early ctDNA changes in predicting disease response, progression, and overall survival outcomes in pts with advanced stage melanoma/skin cancer treated with ICI therapy. Methods: A retrospective analysis using a personalized, tumor-informed ctDNA assay (Natera) on prospectively collected plasma samples from pts with unresectable stage III/IV melanoma/skin cancer treated with anti-PD-1 based therapy at the University of Wisconsin (Madison) was performed. Baseline ctDNA levels were assessed prior to the start of treatment and at 3-4 weeks (i.e. prior to the second treatment dose). A logistic regression model was used to evaluate the odds of overall disease control [complete response + partial response + stable disease, per RECIST version 1.1] based on the change in ctDNA levels (decrease vs increase) between both time points. Cox proportional hazard models were used to investigate the effects of ctDNA level change on progression free survival (PFS) and overall survival (OS). Results: 46 pts were evaluated. 82% melanoma, 14% Merkel cell carcinoma, 2% skin adenocarcinoma and 2% squamous cell carcinoma. 77% were treated with dual ICI (anti-PD-1 based) therapy and 23% with anti-PD-1 monotherapy. Median follow up was 12.1 months. Median change in ctDNA levels from baseline were -4.83 MTM/mL among pts with ctDNA decrease and +37.39 MTM/mL among pts with ctDNA increase. A qualitative decrease in ctDNA level was associated with overall disease control (OR 65.00, 95% CI 11.88-587.89, p<0.0001), longer PFS (HR 0.08, 95% CI 0.03-0.22, p<0.0001), and longer OS (HR 0.17, 95% CI 0.05-0.54, p=0.0008) compared to an increase in ctDNA level from baseline to 3-4 weeks after starting ICI therapy. Median PFS was not reached (NR) and 1.63 months; and median OS was NR and 5.57 months among pts with ctDNA decrease and ctDNA increase, respectively. Conclusions: We found that early ctDNA dynamics after 3-4 weeks of ICI initiation in pts with advanced melanoma/skin cancer appears to be a candidate strategy to predict treatment response, risk of progression, and potentially long-term survival. Larger prospective studies are warranted to validate the utility of ctDNA in treatment monitoring.
Factors predicting long-term survival of hepatocellular carcinoma in developing country.
Authors: Neesanun Sunee 
Published: August 2024

231 Background: Hepatocellular carcinoma (HCC) is a common cancer globally, especially in Asian Pacific countries with survival time limit. Previous data on long-term survival (LS) in HCC patients has been limited. This study aims identifying factors that predict LS for HCC patients treated in hospitals with restricted access to advanced therapies. Methods: This study utilized a retrospective cohort design, analyzing electronic medical records of patients diagnosed with HCC at Sawanpracharak Hospital from October 2018 to September 2022. LS for HCC was defined as survival for two years or more. Univariable and multivariable with stepwise backward regression analyses were employed to identify independent prognostic factors. Results: The analysis included 398 HCC patients, with 75 (18.84%) classified as long-term survivors (LS HCC). Stepwise backward regression identified that ALP levels <172 U/L were associated with a significantly increased likelihood of LS (OR = 3.667, 95% CI 1.443-9.317, p=0.006). Additionally, curative surgery/RFA treatment (OR = 1.941, 95% CI 1.128-3.342, p=0.017) and Albumin >3.5 g/dL (OR = 9.898, 95% CI 1.160- 84.438, p=0.036) were significant positive predictors. ECOG performance status (3-4 vs 2 vs 0-1) and AJCC stage (early vs locally vs advance) also emerged as significant factors, with better performance status (OR = 8.723, 95% CI 1.046-72.741, p=0.045) and AJCC stage 3 and 4 (OR 0.200 95% CI= 0.075-0.532, P= 0.001 and OR = 0.204, 95% CI 0.0547-0.760, p=0.018 respectively) associated with LS. Notably, alcohol consumption was associated with a decreased likelihood of LS (OR = 0.399, 95% CI 0.171-0.929, p=0.033). The model demonstrated good discriminative ability with an AUC of 0.912. Conclusions: Lower ALP levels, curative treatment, higher albumin levels, better ECOG performance status, earlier AJCC stage, and abstinence from alcohol consumption were all associated with a significantly increased likelihood of LS HCC. The high AUC of the model suggests its potential for predicting long-term survival in this patient population. [Table: see text]
The single cell transcriptional landscape of fibrosarcoma.
Authors: Wang Juan , Li Zhenfeng , Zhang Ning 
Published: August 2024

235 Background: Fibrosarcoma (FS) is a relatively uncommon subtype of soft tissue sarcoma, which predominantly occurs in the extremities and girdles of elderly individuals. FS are famous for its high recurrence and metastasis rate. However, the current treatment regimens have shown poor efficacy in treating these progressive lesions. Therefore, a deep understanding of the tumor microenvironment characteristics of fibrosarcoma is needed to develop more effective drugs.Therefore, a deeper understanding of the tumor microenvironment characteristics of fibrosarcoma is needed for further development of therapeutic drugs. Methods: We performed single-cell transcriptome sequencing for the first time on 6 patients bearing with FS. Bulk-seq data of soft tissue sarcoma was downloaded from public database including TCGA and GEO for prognostic analysis. What' s more, a cohort of 54 FS patients was retrospectively collected for protein detection. Results: The tumor microenvironment landscape was characterized by the presence of malignant fibroblast, diverse macrophages, limited T-cell presence, and high levels of vascular infiltration. The expression of siglec15 was significantly upregulated in the malignant cells. And the prognostic significance of siglec15 was confirmed by the TCGA public database. What’s more, the high expression of siglec15 protein was negatively related to overall survival of fibrosarcoma patients from our institution. We also explored the interactions among different cell subtypes, especially the interactions between malignant cells and endothelial cells, as well as macrophages and endothelial cells, which not only promote tumor progression but also inhibit T-cell infiltration and function. Conclusions: In total, our work has uncovered the low T cell infiltration landscape of FS. The primary reason of insufficient immune infiltration may be due to the blockage of T cell extravasation caused by the interaction between endothelial cells, malignant cells and macrophages.
The candidate novel markers PIV and PILE score to predict survival outcomes and therapeutic response in patients with primary central nervous system lymphoma.
Authors: Duan Ling , Li Wenbin , Chen Feng 
Published: August 2024

24 Background: Recent studies highlighted the predictive value of easily measurable blood-based biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR), and the systemic immune-inflammation index (SII). Recently, a novel comprehensive marker that represents the pan-immune-inflammation value (PIV) has been proposed as a more reliable predictor of clinical outcomes. We aimed to investigate the prognostic significance of PIV and PILE score (a score based on PIV, lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group Performance Status (ECOG PS)), in patients with PCNSL. Methods: A total of 109 patients were enrolled. PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The PILE score was calculated with the sum of individual values (for PIV < median = 0, ≥ median = 1; for LDH ≤ upper limit of normal (ULN) = 0, > ULN = 1; for ECOG PS < 2 = 0, ≥ 2 = 1). The Kaplan–Meier method and Cox hazards regression models were used for survival analyses. The relationship between PIV, PILE, and therapeutic response was examined. Results: Pretreatment high PIV was confirmed to be an independent significant factor for overall survival (OS) in univariate (HR 3.990, 95%CI 1.778-8.954, p < 0.001) and multivariate (HR 3.047, 95%CI 1.175-7.897, p = 0.022) analyses. Baseline PIV was also associated with worse progression-free survival (PFS). Regarding OS, PIV showed a better predictive performance than other widely used systemic inflammation parameters. Significantly shorter OS and PFS were observed in the high PILE group (median OS: 25.60, 95% CI 15.60-NR vs. NR months, 95% CI 26.10-NR, p = 0.008; median PFS: 26.13, 95% CI 23.30-NR vs. 7.13 months, 95% CI 4.87-NR, p < 0.001). High PILE was associated with primary resistance to therapy (high PILE group: 21/42 patients, 50.00%; low PILE group: 5/45 patients, 11.11%; p < 0.001). A significantly lower response rate to initial treatment was found in patients in the high PILE group (23/42, 54.76%) as compared to patients in the low PILE group (7/45, 15.56%; p < 0.001). PILE was independently associated with therapeutic response to initial treatment (OR 0.17, 95% CI 0.05–0.46; p < 0.001). Conclusions: High PIV and high PILE were correlated with worse clinical outcomes in PCNSL patients, indicating that PIV and PILE might be a powerful predictor of prognosis and a potential predictive indicator for treatment response in PCNSL.
The use of adjuvant radiotherapy in resected adult intracranial atypical meningioma in United States: A SEER analysis.
Authors: Co Jayson L. 
Published: August 2024

27 Background: It is unclear whether adjuvant external beam radiotherapy (EBRT) in atypical meningiomas after surgical resection provided overall survival advantage. Although meta-analysis were previously reported, there is heterogeneity in the included studies. With lack of prospective trial, we rely on observational data for management. This project aims to determine if the addition of adjuvant EBRT after resection compared to resection alone in atypical meningioma is associated with better prolonged survival among patients within United States. Methods: The National Cancer Institute Surveillance, Epidemiology and End Results database was queried for list of patients diagnosed with atypical meningioma from 2000 to 2020 according to International Classification of Disease (ICD) for Oncology, third edition with morphology codes 9539/0 and 9539/1.This was limited to intracranial location. Rate of dying among those receiving adjuvant EBRT after surgery for atypical meningiomas was compared to the rate of dying of those who had resection alone without adjuvant EBRT postoperatively. Other covariates included, age at diagnosis, gender, marital status, race, tumor laterality, tumor site, tumor, extent of resection and household median income. Chi-squared test was used to test the association between institution of adjuvant EBRT and other co-variates for categorical variable. Cox-proportional analysis was used to test the association between adjuvant EBRT and death. Observed survival was estimated using Kaplan-Meyer method. Survival curves were generated for both cohorts and log rank test was performed. Results: A total of 3,328 patients were included in analysis.1,004(30.17%) patients received adjuvant EBRT and 767(23.05%) died in the entire cohort. Rate of dying in the entire cohort is 43.84 per 1,000 person-years. Death rate for patients receiving adjuvant EBRT is 44.95 per 1,000 person-years, while patients who did not receive adjuvant EBRT had a death rate of 40.95 per 1,000 person-years. Patients aged 80 years or older, divorced and separated tend not to receive adjuvant EBRT, while patients with tumor size of 51-100mm and 101-200mm are more likely to receive adjuvant RT. Crude rate ratio among those patients receiving RT compared to the rate of those who did not receive adjuvant RT is 0.91 (95% CI: 0.76-1.07). Adjusting for possible confounders did not change the rate ratio between adjuvant EBRT compared to resection alone. Extent of resection did not modify the effect of adjuvant RT to death (likelihood ratio test-0.363). Survival analysis using Kaplan Meier curve showed no difference whether a patient received adjuvant EBRT or not (log rank test-0.238). Conclusions: There is no clear evidence on the survival benefit for use of adjuvant EBRT in resected atypical meningioma compared resection alone. This is true both in incomplete and completely resected atypical meningiomas.